查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1978271

全球mRNA疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global mRNA Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 107 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

mRNA疫苗市場預計將從2025年的127.6億美元成長到2034年的274.3億美元，2026年至2034年的複合年成長率為8.88%。

由於傳訊RNA（mRNA）疫苗的成功研發和應用，全球mRNA疫苗市場正迅速成長。這類疫苗利用遺傳訊息刺激人體免疫系統，使其辨識並對抗特定病原體。 mRNA技術在全球疫苗接種宣傳活動中的有效性顯著提升了人們對這種創新疫苗研發方法的興趣。製藥公司和研究機構正大力投資mRNA平台，以開發針對多種感染疾病的疫苗。

推動市場成長的另一個關鍵因素是mRNA疫苗研發的柔軟性和速度。與傳統疫苗技術不同，mRNA平台能夠快速適應並針對新的病毒及其變種。這項特性在應對新出現的健康威脅方面極為寶貴。遞送系統和儲存技術的進步也提高了mRNA疫苗的穩定性和分發效率，從而促進了其在全球的應用。

未來，mRNA市場預計將從感染疾病預防擴展到癌症免疫療法和個人化醫療等領域。目前正在進行的研究和臨床試驗正在探索基於mRNA的療法在多種疾病治療中的潛力。隨著生物技術的不斷創新，mRNA技術有望成為下一代醫療療法的關鍵組成部分。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球mRNA疫苗市場：依應用分類

  • 市場分析、洞察與預測
  • 癌症
  • 感染疾病
  • 其他（自體免疫疾病）

第5章 全球mRNA疫苗市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 政府機構
  • 私人醫院和診所
  • 其他（研究機構、製藥公司、生技公司等）

第6章 全球mRNA疫苗市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Pfizer Inc
    • Moderna Inc
    • Novartis AG
    • Sanofi
    • Arcturus Therapeutics
    • Gennova Biopharmaceuticals Ltd
    • Aimei Vaccine Co. Ltd
簡介目錄
Product Code: VMR112114452

The mRNA Vaccine Market size is expected to reach USD 27.43 Billion in 2034 from USD 12.76 Billion (2025) growing at a CAGR of 8.88% during 2026-2034.

The global mRNA vaccine market has grown rapidly due to the successful development and deployment of messenger RNA-based vaccines. These vaccines use genetic instructions to stimulate the body's immune system to recognize and fight specific pathogens. The effectiveness of mRNA technology during global vaccination campaigns has significantly increased interest in this innovative approach to vaccine development. Pharmaceutical companies and research organizations are investing heavily in mRNA platforms to develop vaccines for a variety of infectious diseases.

Another major factor driving market growth is the flexibility and speed of mRNA vaccine development. Unlike traditional vaccine technologies, mRNA platforms can be quickly adapted to target new viruses or variants. This capability makes them highly valuable in responding to emerging health threats. Advances in delivery systems and storage technologies are also improving the stability and distribution of mRNA vaccines, supporting broader adoption worldwide.

In the future, the market is expected to expand beyond infectious disease prevention into areas such as cancer immunotherapy and personalized medicine. Ongoing research and clinical trials are exploring the potential of mRNA-based treatments for a wide range of diseases. As biotechnology innovation continues to progress, mRNA technology is likely to become a major component of next-generation medical therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

  • Cancer
  • Infectious Disease
  • Others (Autoimmune Diseases)

By End-user

  • Government Entities
  • Private Hospitals & Clinics
  • Others (Research Institutes, Pharmaceutical and Biotechnology Companies, etc.)

COMPANIES PROFILED

  • Pfizer Inc, Moderna Inc, Novartis AG, Sanofi, Arcturus Therapeutics, Gennova Biopharmaceuticals Ltd, Aimei Vaccine Co Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA VACCINE MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Application
  • 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Others (Autoimmune Diseases) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MRNA VACCINE MARKET: BY END-USER 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast End-user
  • 5.2. Government Entities Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Private Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Others (Research Institutes, Pharmaceutical and Biotechnology Companies, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MRNA VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.2.1 By Application
    • 6.2.2 By End-user
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.3.1 By Application
    • 6.3.2 By End-user
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.4.1 By Application
    • 6.4.2 By End-user
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.5.1 By Application
    • 6.5.2 By End-user
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.6.1 By Application
    • 6.6.2 By End-user
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL MRNA VACCINE INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Pfizer Inc
    • 8.2.2 Moderna Inc
    • 8.2.3 Novartis AG
    • 8.2.4 Sanofi
    • 8.2.5 Arcturus Therapeutics
    • 8.2.6 Gennova Biopharmaceuticals Ltd
    • 8.2.7 Aimei Vaccine Co. Ltd